HRAS and breast cancer: Although RAS pathway mutations in primary breast cancer is approximately 2% (12), a recent study involving genomic analyses of 379 metastatic samples from 301 patients found 40%, 24%, 18%, and 12% of metastasis harboring aberrations in H-RAS, K-RAS, M-RAS, and N-RAS genes, respectively (13).